twoXAR Pharmaceuticals, a United States-based drug discovery and development company, has named Howard Rosen as its new director, it was reported on Wednesday.

Rosen has over 25 years of experience in pharmaceutical and biotechnology leadership and strategy. He has held senior leadership positions in various companies including Gilead Sciences Inc and ALZA Corporation. He serves as a board member with AcelRx Pharmaceuticals Inc, Kala Pharmaceuticals Inc, Entrega Inc, Metera Pharmaceuticals Inc and Hammerton Inc.

Andrew Radin, twoXAR CEO, said, 'We are thrilled to have Howie join our board of directors during this exciting time as our discoveries advance closer to IND filings. He has been a trusted advisor to the company since its inception and brings a wealth of experience in leading and advising pharmaceutical companies. We are grateful to have his expertise and insight as we continue to expand our research programs and partnerships.'